LISCure Biosciences receives U.S. FDA Fast Track designation for LB-P8..

LISCure Biosciences receives U.S. FDA Fast Track designation for LB-P8 for the treatment of primary sclerosing cholangit..

2024.04.03

LISCure Biosciences Announces FDA Clearance of IND Application to Init..

FEB 29 2024 14:00 GMT- Represents first ever live biotherapeutic product to receive IND clearance for PSC- Phase 2 clini..

2024.03.04

Celltrion and LISCure Biosciences announce strategic collaboration to ..

■ Co-research and co-development of novel microbiome therapeutics■Discovery of new candidates to meet high unmet medica..

2023.02.21

LISCure's Phase 2 Drug Candidate Granted Orphan Drug Designation (ODD)..

First Orphan Drug Designation (ODD) in the field of microbiome-based treatment for metabolic diseasesSEOUL, South Korea,..

2022.12.09

LISCure Biosciences Announces Oral Presentation of New Drug Candidate ..

The efficacy and mechanism of NASH microbiome-based therapy for liver fibrosis, steatosis, and inflammation have been co..

2022.10.28

LISCure Biosciences Announces Research Collaboration with The Scripps ..

SEOUL, South Korea,Feb. 3, 2022/PRNewswire/ --LISCure Biosciences ("LISCure") announced that it had reached an..

2022.02.03

LISCure Biosciences announces research collaboration with Mayo Clinic ..

SEOUL, South Korea,Jan. 6, 2022/PRNewswire/ -- LISCure Biosciences Inc., a leading biotech focused on microbial-based th..

2022.01.06

LISCure Biosciences received clinical approval for two microbiome prog..

SEOUL, South Korea,Sept. 30, 2021/PRNewswire/ -- LISCure Biosciences ("LISCure") announced that it has receive..

2021.10.01

LISCure Biosciences Announces Know-How License Agreement and Stock Pur..

SEOUL, South Korea, Aug. 1, 2021 /PRNewswire/ -- LISCure Biosciences, Inc. ("LISCure") has entered into a kno..

2021.08.01